0 of 4 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 4 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
You must score 0% to continue. Please click the link below to re-take the quiz
1. Julia is a 42-year-old woman with OA who demonstrates abnormal bone loss, including limited collapse of multiple subchondral surfaces not typical of conventional advanced OA. Which of the following is consistent with her radiological findings?
2. Is Julia an appropriate candidate for tanezumab therapy?
3. What was the most common exclusionary radiographic finding in participants of the clinical trial program for subcutaneous tanezumab for OA?
4. Evaluation of joint safety has found that an increase in rate of adjudicated CJSE (composite joint safety endpoints) associated with tanezumab treatment is correlated with which of the following?